Location [1]
Protein [2]
Histone-lysine N-methyltransferase SMYD3
Synonyms [1]
KMT3E, ZNFN3A1, ZMYND1, bA74P14.1

SMYD3 is altered in 1.09% of all cancers with endometrial endometrioid adenocarcinoma, lung adenocarcinoma, breast invasive ductal carcinoma, cutaneous melanoma, and invasive breast carcinoma having the greatest prevalence of alterations [3].

SMYD3 GENIE Cases - Top Diseases

The most common alterations in SMYD3 are SMYD3 Amplification (0.43%), SMYD3 Loss (0.04%), SMYD3 S154L (0.02%), SMYD3 A252V (0.01%), and SMYD3 R165* (0.01%) [3].

SMYD3 GENIE Cases - Top Alterations


1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.